Sacconi R, et al. – This study is performed to assess the impacts of intravitreal dexamethasone (DEX) implants in patients influenced by diabetic macular edema (DME) with high best–corrected visual acuity (BCVA) and contraindications to therapy with anti–vascular endothelial growth factor over a 12–month follow–up. The DEX implant on a pro re nata basis can be considered a beneficial approach for DME patients with high BCVA over a 12–month follow–up; functional and anatomical outcome of the patients significantly improved with few injections and a good safety profile.